The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
25227627

DOI
10.1136/bmjopen-2014-005376

Indexing Status
Subject indexing assigned by NLM

MeSH
Alcohol Drinking /economics /prevention & control; Alcoholism /drug therapy; Combined Modality Therapy /economics; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Middle Aged; Naltrexone /analogs & derivatives /economics /therapeutic use; Public Health; Risk Assessment; Social Support

AccessionNumber
22014036601

Date bibliographic record published
26/11/2014